Gwen Wyatt1, Alla Sikorskii2, Irena Tesnjak2, David Victorson3, Gordan Srkalovic4. 1. College of Nursing, Michigan State University, 1355 Bogue Street, Room C345, East Lansing, MI, 48824, USA. gwyatt@msu.edu. 2. Department of Statistics and Probability, Michigan State University, 619 Red Cedar Road, Room C423, East Lansing, MI, 48824, USA. 3. Department of Medical Social Sciences, Feinberg School of Medicine, Northwestern University, 2205 Tech Drive, Hogan Building (Suite 2-120), Evanston, IL, 60208, USA. 4. Clinical Trials, Sparrow Health System, 1215 E. Michigan Ave., Lansing, MI, 48912, USA.
Abstract
PURPOSE: Interruptions in medical treatment such as dose delays, reductions, or stoppages can lead to suboptimal treatment of cancer. Knowing how and for whom symptom severity and symptom interference with activities of daily living (ADL) are associated with treatment interruptions can guide behavioral interventions for supportive care. The purpose of this analysis is to inform research and clinical practice by bringing attention to specific patient symptoms that may hinder dose completion. METHODS: A secondary analysis of data collected in a randomized clinical trial (RCT) of reflexology for symptom management was performed. The trial enrolled women with advanced breast cancer undergoing treatment (N = 385). Outcome data were collected at baseline, weeks 5 and 11 using valid and reliable measures. Medical records provided data on treatment interruptions and metastasis. The association between alterations in medical treatment during the study period with symptom severity, symptom interference with ADLs, and metastatic status were tested using generalized estimating equation (GEE) models. RESULTS: The relationship between dose delays and dose reductions and symptom severity was differential according to metastatic status, with the higher strength of association among women with distant metastasis compared to those with loco-regional disease (p = 0.02). The interaction of symptom interference and metastatic status was also significantly related to dose delays and reductions (p = 0.04). Severity of pain was a stronger predictor of dose delays or reductions among patients with distant metastasis compared to those with loco-regional disease (p < 0.01). CONCLUSION: The analysis highlights the importance of understanding symptom outcomes that impact research, practice, and treatment decisions.
RCT Entities:
PURPOSE: Interruptions in medical treatment such as dose delays, reductions, or stoppages can lead to suboptimal treatment of cancer. Knowing how and for whom symptom severity and symptom interference with activities of daily living (ADL) are associated with treatment interruptions can guide behavioral interventions for supportive care. The purpose of this analysis is to inform research and clinical practice by bringing attention to specific patient symptoms that may hinder dose completion. METHODS: A secondary analysis of data collected in a randomized clinical trial (RCT) of reflexology for symptom management was performed. The trial enrolled women with advanced breast cancer undergoing treatment (N = 385). Outcome data were collected at baseline, weeks 5 and 11 using valid and reliable measures. Medical records provided data on treatment interruptions and metastasis. The association between alterations in medical treatment during the study period with symptom severity, symptom interference with ADLs, and metastatic status were tested using generalized estimating equation (GEE) models. RESULTS: The relationship between dose delays and dose reductions and symptom severity was differential according to metastatic status, with the higher strength of association among women with distant metastasis compared to those with loco-regional disease (p = 0.02). The interaction of symptom interference and metastatic status was also significantly related to dose delays and reductions (p = 0.04). Severity of pain was a stronger predictor of dose delays or reductions among patients with distant metastasis compared to those with loco-regional disease (p < 0.01). CONCLUSION: The analysis highlights the importance of understanding symptom outcomes that impact research, practice, and treatment decisions.
Entities:
Keywords:
Breast cancer; Supportive care; Symptom management; Treatment interruptions
Authors: N J Vogelzang; W Breitbart; D Cella; G A Curt; J E Groopman; S J Horning; L M Itri; D H Johnson; S L Scherr; R K Portenoy Journal: Semin Hematol Date: 1997-07 Impact factor: 3.851
Authors: Andrea A Thornton; Lisa Madlensky; Shirley W Flatt; Robert M Kaplan; John P Pierce Journal: Breast Cancer Res Treat Date: 2005-07 Impact factor: 4.872
Authors: Charles Given; Barbara Given; Mohammad Rahbar; Sangchoon Jeon; Ruth McCorkle; Bernadine Cimprich; Andrzej Galecki; Sharon Kozachik; Albert Brady; Mary Jo Fisher-Malloy; Kathy Courtney; Elizabeth Bowie Journal: J Clin Oncol Date: 2004-02-01 Impact factor: 44.544
Authors: Kristine L Kwekkeboom; Lauren Tostrud; Erin Costanzo; Christopher L Coe; Ronald C Serlin; Sandra E Ward; Yingzi Zhang Journal: J Pain Symptom Manage Date: 2018-01-31 Impact factor: 3.612
Authors: Nayan Lamba; Elie Mehanna; Rachel B Kearney; Paul J Catalano; Daphne A Haas-Kogan; Brian M Alexander; Daniel N Cagney; Kathleen A Lee; Ayal A Aizer Journal: Neuro Oncol Date: 2020-09-29 Impact factor: 12.300
Authors: Christine M Gunn; Michael K Paasche-Orlow; Sharon Bak; Na Wang; Jennifer Pamphile; Kerrie Nelson; Samantha Morton; Tracy A Battaglia Journal: JCO Oncol Pract Date: 2020-03-27
Authors: Kah Poh Loh; Chandrika Sanapala; Michelle Janelsins; Heidi D Klepin; Rebecca Schnall; Eva Culakova; Michael B Sohn; Paula Vertino; Martha Susiarjo; Marielle Jensen-Battaglia; Michael W Becker; Jane Liesveld; Jason H Mendler; Eric Huselton; Po-Ju Lin; Karen Mustian Journal: J Geriatr Oncol Date: 2021-12-21 Impact factor: 3.929